WAY vs MTEX vs HIMS vs NVCR vs TDOC

For growth investors, Hims & Hers Health, Inc.

(HIMS) is the stronger pick with 59. 0% revenue growth year-over-year, versus -8. 3% for Mannatech, Incorporated (MTEX). Waystar Holding Corp. (WAY) offers the better valuation at 30. 7x trailing P/E (11. 4x forward), making it the more compelling value choice. Analysts rate Waystar Holding Corp. (WAY) a "Buy" — based on 17 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Waystar Holding Corp.

(WAY) is the cheapest at 30. 7x versus Hims & Hers Health, Inc. at 52. 6x.

Over the past 5 years, Hims & Hers Health, Inc.

(HIMS) delivered a total return of +107. 9%, compared to -95. 3% for Teladoc Health, Inc. (TDOC). Over 10 years, the gap is even starker: HIMS returned +173. 7% versus TDOC's -41. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Mannatech, Incorporated (MTEX) is the lower-risk stock at 0.

44β versus Hims & Hers Health, Inc. 's 2. 48β — meaning HIMS is approximately 464% more volatile than MTEX relative to the S&P 500. On balance sheet safety, Waystar Holding Corp. (WAY) carries a lower debt/equity ratio of 39% versus 2% for Hims & Hers Health, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Hims & Hers Health, Inc.

(HIMS) is pulling ahead at 59. 0% versus -8. 3% for Mannatech, Incorporated (MTEX). On earnings-per-share growth, the picture is similar: Waystar Holding Corp. grew EPS 569. 2% year-over-year, compared to -706. 1% for Mannatech, Incorporated. Over a 3-year CAGR, HIMS leads at 64. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Waystar Holding Corp.

(WAY) is the more profitable company, earning 10. 2% net margin versus -20. 8% for NovoCure Limited — meaning it keeps 10. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: WAY leads at 24. 2% versus -23. 5% for NVCR. At the gross margin level — before operating expenses — MTEX leads at 74. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for WAY: 90.

0% to $35. 62.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Mannatech, Incorporated (MTEX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

44)). NovoCure Limited (NVCR) carries a higher beta of 2. 21 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MTEX: -39. 9%, NVCR: +62. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (WAY (Technology) and MTEX (Consumer Defensive) and HIMS (Healthcare) and NVCR (Healthcare) and TDOC (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: WAY is a small-cap high-growth stock; MTEX is a small-cap quality compounder stock; HIMS is a small-cap high-growth stock; NVCR is a small-cap quality compounder stock; TDOC is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.